Participated · Series B · Jan 2026

Ethernovia is a San Jose–based semiconductor company creating a new class of automotive and edge packet processors designed to aggregate, route and manage high-bandwidth sensor, vision and AI data with deterministic latency and leading power efficiency. Its unified, Ethernet-centric architecture enables zonal and centralized systems that simplify vehicle and robot design while supporting advanced driver assistance, autonomous driving and other real-time, safety-critical applications. The processors provide a flexible, programmable data fabric that can evolve through over-the-air updates, allowing OEMs to deploy software-defined platforms that grow in capability over time. Ethernovia positions its technology as the “nervous system” for physical AI, addressing networking bottlenecks that legacy in-vehicle and industrial networks cannot handle. The firm plans to use new capital to accelerate development and production of its next-generation packet processor family, broaden software and system capabilities, and deepen customer engagements across automotive, robotics and industrial markets. Specific financial or user metrics were not disclosed in the article.

Participated · Series C · Jan 2026

Ukko is developing next-generation allergy treatments by re-engineering allergenic proteins and delivering them via mRNA/LNP formulations to avoid severe reactions while retraining the immune system. Its lead drug candidate, UKK-0018, targets peanut allergy and has shown strong tolerability and protection against anaphylaxis in animal models. Regulatory clearance has been secured in Australia and New Zealand to launch a Phase 1/2a trial in 1H 2026 that will enroll roughly 32–40 adult subjects, with initial data expected in early 2027. The company’s proprietary platform is intended to be scalable to additional allergens such as milk, tree nuts, and respiratory triggers. Ukko recently strengthened its leadership team by appointing Matt Ottmer as COO and Grace Chen-Philips, M.D., as CMO. Headquartered in Boston, Massachusetts, and Rechovot, Israel, Ukko believes its approach can overcome safety and tolerability limitations of existing exposure-based desensitization methods. A $45 million Series C round is expected to fund operations, including the planned clinical study, through 2027.

Participated · Equity · Dec 2025

Ripple Foods develops and sells dairy-free products—primarily plant-based milks, protein shakes, and half-and-half—made from yellow-pea protein that deliver up to 20 g of protein per serving while avoiding common allergens such as nuts, soy, and lactose. The products contain 50 % more calcium than dairy milk, less sugar and fewer calories, and are marketed as pediatrician-recommended and family-friendly. Available nationwide through retailers like Whole Foods, Target, Kroger, and Walmart, Ripple has achieved consistent double-digit top-line growth by capitalizing on the $23 B alternative-protein market. The company is a Certified B-Corporation and emphasizes sustainable production that uses significantly less water than dairy. With a loyal customer base, Ripple plans to launch an organic milk line in Q1 2026, deepen penetration of its core and high-protein kids’ milks, and enter food-service channels. Recently appointed CEO Becky O’Grady, a former General Mills executive and long-time Ripple board member, will lead these initiatives. The firm aims to expand distribution, drive brand visibility, and move toward profitability with the backing of its latest financing.

Participated · Series B · Oct 2025

Ansa Biotechnologies is a DNA synthesis company based in Emeryville, CA that focuses on producing sequence-perfect clonal DNA and sequence-verified linear double-stranded DNA fragments. Its platform aims to give scientists rapid, accurate access to synthetic DNA for applications across healthcare, life sciences, and other industries. To reinforce reliability, the company recently launched the Ansa On-Time Guarantee, promising that any order not shipped in full and on time will be provided free of charge. It has also rolled out a new pricing framework targeting low-complexity DNA sequences to make routine orders more cost-effective. With its latest capital infusion, Ansa plans to expand U.S. manufacturing capacity, deepen customer-experience initiatives, and strengthen strategic partnerships while advancing its technology stack. Although no revenue or user figures were disclosed, the firm’s continued fundraising indicates growing market traction and operational scaling needs.

Participated · Series A · Jan 2025

Bonsai Robotics builds vision-based physical AI solutions for orchard and specialty-crop agriculture, with a flagship product called Visionsteer™ that offers data insights, crop analysis, job planning, notifications and autonomous vehicle control. The company’s technology is designed to operate in GNSS-denied environments and without cellular or internet connectivity, addressing harsh field conditions like dust, darkness, debris and vibration. Bonsai has deployed over 40 integrated autonomous units across the U.S. and Australia and has collected data from operations on more than 500,000 acres. The new funding will be used to enhance its vision-based autonomous software, expand its physical AI platform and dataset, grow OEM partnerships, and accelerate commercialization. Bonsai positions its approach as addressing labor shortages, rising grower costs, climate change and food-security challenges in specialty agriculture. Bonsai Robotics, based in San Jose, CA, provides computer vision-based robotic automation solutions for harsh, off-road environments such as agriculture. Its systems integrate with OEM equipment to enable autonomy and can operate without GPS in adverse conditions including dust, debris and vibration. Led by CEO Tyler Niday, the company works with OEMs including OMC and Flory Industries and with California growers who report significant efficiency gains amid a severe labor shortage. The company raised $13.5M in Seed funding and plans to use the proceeds to accelerate its product roadmap and invest in hiring and sales and marketing. Its product focus is on ruggedizing autonomy for environments where traditional GPS-reliant approaches fail.